FDA to Conclude Abortion Pill Safety Review by March

Why it matters locally: While not directly targeting Tennessee, the FDA's decision on mifepristone's distribution could impact healthcare access and services across the state, affecting clinics and individuals. Any changes to the regulatory framework for medication abortion could alter how these services are provided within Tennessee.

The Food and Drug Administration (FDA) announced it will complete its safety review of the abortion pill mifepristone by March. This timeline follows a federal judge's order in Louisiana, which required the agency to provide an update on its ongoing study. The judge's order is part of a broader lawsuit. This legal action aims to overturn a specific provision that permits mifepristone to be delivered through the mail. The lawsuit challenges the regulatory framework surrounding the drug's distribution. Mifepristone is one of two medications used in medication abortions. The FDA has approved its use since 2000. The agency has periodically reviewed its prescribing and dispensing guidelines.